Find Funding Opportunities

Returning 141 results

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)

PAR
Thursday, March 9, 2017
Translational Research
Friday, May 8, 2020
U44
PAR-17-201
Amir Tamiz, Ph.D.

Funding Opportunity Purpose

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3)

PAR
Thursday, March 9, 2017
Friday, May 8, 2020
UG3/UH3
PAR-17-205

Funding Opportunity Purpose

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and in Health Disparities Populations (UG3/UH3)

RFA
Tuesday, March 7, 2017
Wednesday, May 10, 2017
UG3/UH3
RFA-NS-17-012

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to invite applications that address the unmet need to detect cognitive impairment, including dementia, in large and diverse populations seen in primary care across the United States, including in health disparities populations, when a patient, relative, or care provider indicates concern. Proposed clinical paradigms should utilize tools that are simple to use, standardized, and ideally take five minutes or less to administer in a primary care clinical setting.

NINDS Postdoctoral Mentored Career Development Award (K01)

PAR
Tuesday, January 31, 2017
Wednesday, January 8, 2020
K01
PAR-17-145

Funding Opportunity Purpose

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field.

Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24)

RFA
Friday, January 27, 2017
Wednesday, May 3, 2017
U24
RFA-NS-17-022

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to invite new cooperative agreement applications for the Data Management and Coordinating Center (DMCC), which supports the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC). This FOA will support the DMCC (U24) cooperative agreement that will focus on providing the infrastructure and support to the individual ME/CFS CRCs in their activities. Clinical data management for efficient data collection as well as data mining and data sharing will be addressed in the data management and coordinating center (DMCC). The ME/CFS CRCs will establish a network to facilitate research through: 1) collaborative basic and/or clinical research on ME/CFS; 2) longitudinal studies of individuals with ME/CFS within each ME/CFS CRC and across CRCs within the network; 3) access to information related to ME/CFS for basic and clinical researchers, academic and practicing physicians, healthcare professionals, patients, and the lay public.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54)

RFA
Friday, January 27, 2017
Wednesday, May 3, 2017
U54
RFA-NS-17-021

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC). The overarching goal of this initiative is to establish a network of Centers that will work collaboratively to define the cause(s) of and discover improved treatments for ME/CFS. A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as local resources and national leaders in ME/CFS research. Successful CRC research programs will facilitate research in ME/CFS through conducting of 1) collaborative basic and/or clinical research on ME/CFS; 2) longitudinal studies of individuals with ME/CFS within each ME/CFS CRC and across CRCs within the network; 3) access to information related to ME/CFS for basic and clinical researchers, academic and practicing physicians, healthcare professionals, patients, and the lay public. Clinical data management for efficient data collection as well as data mining and data sharing will be addressed through the separate data management and coordinating center (DMCC). Institutions must be committed to the establishment and continuation of the proposed ME/CFS CRC. Funding decisions will focus on those applications most likely to make highly impactful contributions to ME/CFS research, as well as on those with the greatest potential to collaborate effectively across the ME/CFS CRC program.

Research Program Award (R35)

RFA
Thursday, January 19, 2017
Monday, May 8, 2017
R35
RFA-NS-17-020

Funding Opportunity Purpose

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose outstanding records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II) This greater funding stability will provide investigators with increased freedom and flexibility which may allow them to be more adventurous in their research, to take greater risks, to embark upon research that breaks new ground, to undertake research projects that require a longer timeframe, and/or to extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program.

Zika Virus (ZIKV) Complications (R21)

PA
Tuesday, January 17, 2017
Wednesday, January 8, 2020
R21
PA-17-085

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research on Zika virus (ZIKV) and its complications. This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017.

NINDS Exploratory Clinical Trials (R01)

PAR
Tuesday, January 10, 2017
Wednesday, January 8, 2020
R01
PAR-17-122

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

NINDS Efficacy Clinical Trials (U01)

PAR
Friday, January 6, 2017
Wednesday, January 8, 2020
U01
PAR-17-102

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

Pages